Cargando…
QSAR Evaluations to Unravel the Structural Features in Lysine-Specific Histone Demethylase 1A Inhibitors for Novel Anticancer Lead Development Supported by Molecular Docking, MD Simulation and MMGBSA
Using 84 structurally diverse and experimentally validated LSD1/KDM1A inhibitors, quantitative structure–activity relationship (QSAR) models were built by OECD requirements. In the QSAR analysis, certainly significant and understated pharmacophoric features were identified as critical for LSD1 inhib...
Autores principales: | Jawarkar, Rahul D., Bakal, Ravindra L., Mukherjee, Nobendu, Ghosh, Arabinda, Zaki, Magdi E. A., AL-Hussain, Sami A., Al-Mutairi, Aamal A., Samad, Abdul, Gandhi, Ajaykumar, Masand, Vijay H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332886/ https://www.ncbi.nlm.nih.gov/pubmed/35897936 http://dx.doi.org/10.3390/molecules27154758 |
Ejemplares similares
-
QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads
por: Jawarkar, Rahul D., et al.
Publicado: (2022) -
Identification of potent aldose reductase inhibitors as antidiabetic (Anti-hyperglycemic) agents using QSAR based virtual Screening, molecular Docking, MD simulation and MMGBSA approaches
por: Bakal, Ravindra L., et al.
Publicado: (2022) -
QSAR based virtual screening derived identification of a novel hit as a SARS CoV-229E 3CL(pro) Inhibitor: GA-MLR QSAR modeling supported by molecular Docking, molecular dynamics simulation and MMGBSA calculation approaches
por: Jawarkar, R.D., et al.
Publicado: (2022) -
Mechanistic Analysis of Chemically Diverse Bromodomain-4 Inhibitors Using Balanced QSAR Analysis and Supported by X-ray Resolved Crystal Structures
por: Zaki, Magdi E. A., et al.
Publicado: (2022) -
In-silico studies to recognize repurposing therapeutics toward arginase-I inhibitors as a potential onco-immunomodulators
por: Zaki, Magdi E. A., et al.
Publicado: (2023)